



UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY-DOCKET NO.
09/201,228	11/30/98	GRIFFITHS	9710-004

PENNIE & EDMONDS
155 AVENUE OF THE AMERICAS
NEW YORK NY 10036-2711

HM12/0417

EXAMINER

ART UNIT

PAPER NUMBER

(Transferred Out)

DATE MAILED:

4/17/02 #11

Amendment: 7/17/01

(CM)

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Carolee Garcia
APR 23 2001Approved w/
Examiner
4/17/01
was date
mailed
4/29/01

REFERRED TO <u>Chen</u> REC'D
APR 20 2001
Pennie & Edmonds O.K. for filing

Office Action Summary

Application No.
09/201,228

Applicant(s)

Griffais t al.

Examiner

Ardin Marschel

Group Art Unit

1631



☒ Responsive to communication(s) filed on Jan 18, 2001

☐ This action is **FINAL**.

☐ Since this application is in condition for allowance except for formal matters, **prosecution as to the merits is closed** in accordance with the practice under *Ex parte Quayle*, 35 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claim

☒ Claim(s) 1-56 is/are pending in the application

Of the above, claim(s) 17-29, 31-50, and 53-56 is/are withdrawn from consideration

☐ Claim(s) _____ is/are allowed.

☒ Claim(s) 1-16, 30, 51, and 52 is/are rejected.

☐ Claim(s) _____ is/are objected to.

☒ Claims 1-56 are subject to restriction or election requirement.

Application Papers

☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

☐ The drawing(s) filed on _____ is/are objected to by the Examiner.

☐ The proposed drawing correction, filed on _____ is ☐ approved ☐ disapproved.

☐ The specification is objected to by the Examiner.

☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

☐ All ☐ Some* ☒ None of the CERTIFIED copies of the priority documents have been

☐ received.

☐ received in Application No. (Series Code/Serial Number) _____

☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____

☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

☒ Notice of References Cited, PTO-892 (3 sheets)

☒ Information Disclosure Statement(s), PTO-1449, Page 802 (4 sheets)

☐ Interview Summary, PTO-413

☐ Notice of Draftsperson's Patent Drawing Review, PTO-948

☐ Notice of Informal Patent Application, PTO-152

— SEE OFFICE ACTION ON THE FOLLOWING PAGES —

Applicants' election of Group I (claims 1-16, 30, 51, and 52) and nucleic acid sequences of ORFs 1083, 1089, 1091, 1095, 1096, 1105, 1117, 1140, 1159, and 1167 in Paper No. 8, filed 8/16/00, is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (M.P.E.P. § 818.03(a)).

The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed. The present title is directed to numerous compositions and methods whereas in contrast only nucleic acid molecules, recombinant vectors, a DNA chip, recombinant host cells, and kits are contained in the elected claims.

The pending claims have been reviewed in light of the Utility Examination Guidelines and Guidelines for Examination of Patent Applications under 35 U.S.C. 112, first paragraph, "Written Description" Requirement, Federal Register, Vol. 66, No. 4, pages 1092-1111, Friday, January 5, 2001.

The examiner is using the following definitions in evaluating the claims for utility.

"Specific" - A utility that is *specific* to the subject matter claimed. This contrasts with a *general* utility that would be applicable to the broad class of the invention.

"Substantial" - A utility that defines a "real world" use. Utilities that require or constitute carrying out further research to identify or reasonably confirm a "real world" context of use are not substantial utilities.

"Credible" - Credibility is assessed from the perspective of one of ordinary skill in the art in view of the disclosure and any other evidence of record that is probative of the applicant's assertions. That is, the assertion is an inherently unbelievable undertaking or involves implausible scientific principles.

"Well-established" - a specific, substantial, and credible utility which is well known, immediately apparent, or implied by the specification's disclosure of the properties of a material, alone or taken with the knowledge of one skilled in the art.

35 U.S.C. § 101 reads as follows:

"Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter or any new and useful improvement thereof, may obtain a patent therefore, subject to the conditions and requirements of this title".

Claims 1-16, 30, 51, and 52 are rejected under 35 U.S.C. § 101 because the claimed invention lacks patentable utility due to its not being supported by either specific and/or substantial utility or a well established utility.

The claimed nucleic acids are not supported by a specific asserted utility because the disclosed uses of these compositions

are not specific and are generally applicable to any nucleic acid. The specification states that the nucleic acid compounds may be useful as markers, the isolation of polypeptides, hybridization probes, primers, could be used to make protein and optionally further usage for mapping and numerous other generic genetic engineering usages, as well as diagnosis. In fact, the specification summarized modern biotechnology generally but never connects any of the specifically elected sequences to any particular or specific utility. This wishlist desire for a utility for the claimed sequences falls short of a readily available utility. Similarly, protein may be used for detection of expression, antibody production, Western blots, etc. These are non-specific uses that are applicable to nucleic acid(s) and/or proteins in general and not particular or specific to the nucleic acids being claimed.

Further, the claimed nucleic acids are not supported by a substantial utility because no substantial utility has been established for the claimed subject matter. For example, a nucleic acid may be utilized to obtain a protein. The protein could then be used in conducting research to functionally characterize the protein. The need for such research clearly indicates that the protein and/or its function is not disclosed as to a currently available or substantial utility. A starting material that can only be used to produce a final product does not have substantial asserted utility in those instances where

the final product is not supported by a specific and substantial utility. In this case none of the proteins that are to be produced as final products resulting from processes involving claimed nucleic acid have asserted or identified specific and substantial utilities. The research contemplated by applicant(s) to characterize potential protein products, especially their biological activities, does not constitute a specific and substantial utility. Identifying and studying the properties of a protein itself or the mechanisms in which the protein is involved does not define a "real world" context or use. Similarly, the other listed and asserted utilities as summarized above or in the instant specification are neither substantial nor specific due to being generic in nature and applicable to a myriad of such compounds. Note, because the claimed invention is not supported by a specific and substantial asserted utility for the reasons set forth above, credibility has not been assessed. Neither the specification as filed nor any art of record discloses or suggests any property or activity for the nucleic acid and/or protein compound(s) such that another non-asserted utility would be well established for the compounds.

Specifically the Table 1 information for each elected sequence is herein reviewed: ORF

ORF	homologous sequence
1083	putative
1089	putative

1091 putative
1095 putative
1096 putative
1105 putative
1117 putative
1140 putative
1159 putative
1167 putative

These "putative" assignments of a ORF is deemed to clearly lack specific and/or substantial utility and is clearly non-enabling as to how to use such sequences.

The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-16, 30, 51, and 52 are also rejected under 35 U.S.C. § 112, first paragraph. Specifically, since the claimed invention is not supported by a specific, substantial, and credible utility, or, alternatively, a well established utility for the reasons set forth above, one skilled in the art would not know how to use the claimed invention.

Claims 1-16, 30, 51, and 52 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which

was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The specification discloses the elected SEQ ID NOs. which corresponds in some undefined way to cDNA/genomic DNA encoding bacterial species of protein/nucleic acid. The elected SEQ ID NOs per se meet the written description and enablement provisions of 35 USC 112, first paragraph. However, claims 1-16, 30, 51, and 52 are directed to encompass gene sequences, and fragments of sequences of the elected SEQ ID NOs., corresponding sequences from other species that hybridize thereto, mutated fragment sequences, allelic variants, splice variants, and so forth. None of these additional sequences meet the written description provision of 35 USC 112, first paragraph. The specification provides insufficient written description to support the genus encompassed by the claim. This is a rejection based on a lack of WRITTEN DESCRIPTION.

Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, makes clear that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the 'written description' inquiry, *whatever is now claimed*." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See Vas-Cath at page 1116.)

With the exception of the elected SEQ ID NOs.; the skilled artisan cannot envision the detailed chemical structure of the

encompassed polynucleotides, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it. The nucleic acid itself is required. See Fiers v. Revel, 25 USPQ2d 1601, 1606 (CAFC 1993) and Amgen Inc. V. Chugai Pharmaceutical Co. Ltd., 18 USPQ2d 1016. In Fiddes v. Baird, 30 USPQ2d 1481, 1483, claims directed to mammalian FGF's were found unpatentable due to lack of written description for the broad class. The specification provided only the bovine sequence.

Finally, University of California v. Eli Lilly and Co., 43 USPQ2d 1398, 1404, 1405 held that:

...To fulfill the written description requirement, a patent specification must describe an invention and do so in sufficient detail that one skilled in the art can clearly conclude that "the inventor invented the claimed invention." Lockwood v. American Airlines, Inc., 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (1997); In re Gosteli, 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989) (" [T]he description must clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed."). Thus, an applicant complies with the written description requirement "by describing the invention, with all its claimed limitations, not that which makes it obvious," and by using "such descriptive means as words, structures, figures, diagrams, formulas, etc., that set forth the claimed invention." Lockwood, 107 F.3d at 1572, 41 USPQ2d at 1966.

An adequate written description of a DNA, such as the cDNA of the recombinant plasmids and microorganisms of the '525 patent, "requires a precise definition, such as by structure, formula, chemical name, or physical properties," not a mere wish or plan for obtaining the claimed chemical invention. Fiers v. Revel, 984 F.2d 1164, 1171, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993). Accordingly, "an

adequate written description of a DNA requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it; what is required is a description of the DNA itself." Id. at 1170, 25 USPQ2d at 1606.

The name cDNA is not itself a written description of that DNA; it conveys no distinguishing information concerning its identity. While the example provides a process for obtaining human insulin-encoding cDNA, there is no further information in the patent pertaining to that cDNA's relevant structural or physical characteristics; in other words, it thus does not describe human insulin cDNA. Describing a method of preparing a cDNA or even describing the protein that the cDNA encodes, as the example does, does not necessarily describe the cDNA itself. No sequence information indicating which nucleotides constitute human cDNA appears in the patent, as appears for rat cDNA in Example 5 of the patent. Accordingly, the specification does not provide a written description of the invention of claim 5.

Therefore, only the elected SEQ ID NOs. but not the full breadth of the claims meet the written description provision of 35 USC 112, first paragraph. The species specifically disclosed are not representative of the genus because the genus is highly variant. Applicant is reminded that Vas-Cath makes clear that the written description provision of 35 USC 112 is severable from its enablement provision. (See page 1115.)

It is also noted that the above "putative" sequence assignments causes there to be an additional lack of written description as to which sequences correspond to which enzyme genes as listed in instant claim 7.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-7, 51, and 52 are rejected under 35 U.S.C. § 102(a) or (b) as being clearly anticipated by the various Genbank sequences listed for each instantly elected SEQ ID NO. wherein they have greater than 80% identity and thus also hybridize under high stringency conditions to the instant sequences or their full and exact complement of the same length. Certain sequences have greater than about 40%, but less than 80%, sequence identity and are the basis for rejecting only claims 3, 6, 7, 51, and 52. The 102(a) versus 102(b) type of Genbank sequence is determined by the publication date for each sequence where 102(a) sequences were published as prior art on or after November 28, 1996 and 102(b) prior art sequences were published before November 28, 1996.

Instant SEQ ID NO:	Genbank acc. no.	% similarity	102 sec.
1083	X68033	60	102 (b)
1089	M74221	99.115	102 (b)
1091	Z11839	65.714	102 (a)
1095	T67502	63.492	102 (a)
1096	Q54841	44.444	102 (b)

1105	X63515	75.904	102(a)
1117	U76535	52.688	102(a)
1140	L35530	60.440	102(b)
1159	X59601	58.252	102(a)
1167	N70920	56.863	102(b)

The following is a quotation of 35 U.S.C. § 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. § 103, the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 C.F.R. § 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of potential 35 U.S.C. § 102(f) or (g) prior art under 35 U.S.C. § 103(a).

Claims 1-7, 9-11, 13, 15, 51, and 52 are rejected under 35

U.S.C. § 103(a) as being unpatentable over the below GenBank sequences corresponding to each instant elected SEQ ID NO.

The sequences disclosed in the Genbank sequence alignments as listed below are disclosed as to one strand but are prepared as cDNAs from isolated mRNAs which suggests and motivates complements thereof as well as host cells which must contain operatively linked regulatory sequences in order for these sequences to have been grown and isolated therefrom. It is noted that the instant claims are not limited as to what % complementarity is meant by the stringency or hybridizability limitations in the claims.

Instant SEQ ID NO: Genbank acc. no.

1083	X68033
1089	M74221
1091	Z11839
1095	T67502 ✓
1096	Q54841 ✓
1105	X63515 ✓
1117	U76535 ✓
1140	L35530 ✓
1159	X59601 ✓
1167	N70920 ✓

Thus, it would have been obvious to someone of ordinary skill in the art at the time of the instant invention to prepare the mRNAs, cDNAs, host cells containing them, in vectors with

operative regulatory sequences thus resulting in embodiments of the instant invention.

Claim 30 is rejected under 35 U.S.C. § 103(a) as being unpatentable over the above listed GenBank sequences corresponding to each instant elected SEQ ID NO:, taken in view of Southern et al. (P/N 5,436,327).

The above sequence matches describe nucleic acids within the scope of the instant claims as being of interest. Southern et al. describes the preparation and use of DNA chips whereon such nucleic acids of interest are immobilized.

Thus, it would have been obvious to someone of ordinary skill in the art at the time of the instant invention to immobilize interesting nucleic acids as listed above as motivated and suggested regarding such immobilization by Southern et al. thus resulting in the practice of instant claim 30.

No claim is allowed.

Papers related to this application may be submitted to Technical Center 1600 by facsimile transmission. Papers should be faxed to Technical Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993) (See 37 CFR § 1.6(d)). The CM1 Fax Center number is either (703)308-4242 or (703)305-3014.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ardin Marschel, Ph.D., whose telephone number is (703)308-3894. The examiner can normally be reached on Monday-Friday from 8 A.M. to 4 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, Ph.D.,

Serial No. 09/201,228


- 14 -

Art Unit: 1631

can be reached on (703)308-4028.

Any inquiry of a general nature or relating to the status of this application should be directed to Patent Analyst, Tina Plunkett, whose telephone number is (703)305-3524 or to the Technical Center receptionist whose telephone number is (703) 308-0196.

April 6, 2001


ARDIN H. MARSCHEL
PRIMARY EXAMINER